Formulary Group work programme


Forthcoming submissions 2014

This list is indicative and may be subject to change.

Aflibercept - SMC 1003/14 - in progress. (Indication: for adults for the treatment of visual impairment due to diabetic macular oedema (DMO)).

Atomoxetine - SMC 909/13 - in progress. (Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme).

Botulinum Toxin - SMC 931/13 - Formulary Group advice will be published by 2nd December 2014. (Indication: the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency).

Brinzolamide/brimonidine tartrate eye drops (Simbrinza®) - SMC 991/14 - Formulary Group advice will be published by 2nd December 2014. (Indication: decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction).

Daclatasvir - SMC 1002/14 - Formulary Group advice will be published by 2nd December 2014. (Indication: in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults).

Denosumab - SMC 1013/14 - Formulary Group advice will be published by 2nd December 2014. (Indication: osteoporosis in men at increased risk of fractures).

Eltrombopag - SMC 919/13 - in progress. (Indication: in adult patients with chronic hepatitis C virus infection, for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy).

Everolimus - SMC 595/10 - in progress. (Indication: the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy).

Ipilimumab - SMC 997/14 - Formulary Group advice will be published by 2nd December 2014. (Indication: treatment of advanced (unresectable or metastatic) melanoma in adults (first-line use)).

Mifepristone tablet and misoprostol vaginal tablets combipack (Medabon®) - SMC 913/13 - Formulary Group advice will be published by 2nd December 2014. (Indication: for medical termination of developing intra-uterine pregnancy of up to 63 days of amenorrhoea).

Misoprostol - SMC 996/14 - Formulary Group advice will be published by 2nd December 2014.  (Indication: induction of labour in women with an unfavourable cervix, from 36 weeks gestation, in whom induction is clinically indicated).

Nalmefene - SMC 917/13 - in progress. (Indication: for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms, and who do not require immediate detoxification).

Nepafenac - SMC 813/12 - in progress. (Indication: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients).

Ondanestron - SMC 912/13 - in progress. (Indication: in adults: prophylaxis and treatment of acute and delayed nausea and vomiting induced by chemotherapy, and radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting.
In paediatric populations: management of chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years).

Ocriplasmin - SMC 892/13 - in progress. (Indication: in adults for the treatment of vitreomacular traction).

Rituximab subcutaneous injection - SMC 975/14 - in progress. (Indication: for non-Hodgkin's lymphoma (NHL) in adults).

Saxagliptin - SMC 772/12 - Formulary Group advice will be published by 2nd December 2014. (Indication: in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as combination therapy with insulin (with or without metformin)).

Vitaros® - FG1 369/14 - Formulary Group advice will be published 2nd December 2014. (Indication: erectile dysfunction).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

« Previous: Formulary Group | Top | Next: Formulary Group decisions index »